These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 28225313)
1. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. Cunningham G; Belkoff L; Brock G; Efros M; Gittelman M; Carrara D; Neijber A; Ando M; Mitchel J Endocr Pract; 2017 May; 23(5):557-565. PubMed ID: 28225313 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies. Belkoff L; Brock G; Carrara D; Neijber A; Ando M; Mitchel J Andrologia; 2018 Feb; 50(1):. PubMed ID: 28295450 [TBL] [Abstract][Full Text] [Related]
3. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
4. A novel testosterone 2% gel for the treatment of hypogonadal males. Dobs AS; McGettigan J; Norwood P; Howell J; Waldie E; Chen Y J Androl; 2012; 33(4):601-7. PubMed ID: 21979302 [TBL] [Abstract][Full Text] [Related]
5. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357 [TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881 [TBL] [Abstract][Full Text] [Related]
7. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. Gittelman M; Jaffe JS; Kaminetsky JC J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193 [TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Morrison BF; Reid M; Madden W; Burnett AL Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509 [TBL] [Abstract][Full Text] [Related]
9. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Rhoden EL; Morgentaler A Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827 [TBL] [Abstract][Full Text] [Related]
10. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745 [TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867 [TBL] [Abstract][Full Text] [Related]
12. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800 [TBL] [Abstract][Full Text] [Related]
14. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index. Dobs A; Norwood P; Potts S; Gould E; Chitra S J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410 [TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. Coward RM; Simhan J; Carson CC BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450 [TBL] [Abstract][Full Text] [Related]
16. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Arver S; Stief C; de la Rosette J; Jones TH; Neijber A; Carrara D Andrology; 2018 May; 6(3):396-407. PubMed ID: 29600542 [TBL] [Abstract][Full Text] [Related]
17. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies. Efros M; Carrara D; Neijber A Andrologia; 2016 Aug; 48(6):637-45. PubMed ID: 26598279 [TBL] [Abstract][Full Text] [Related]
18. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Dobs AS; Matsumoto AM; Wang C; Kipnes MS Curr Med Res Opin; 2004 May; 20(5):729-38. PubMed ID: 15140340 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Wang C; Ilani N; Arver S; McLachlan RI; Soulis T; Watkinson A Clin Endocrinol (Oxf); 2011 Dec; 75(6):836-43. PubMed ID: 21689131 [TBL] [Abstract][Full Text] [Related]
20. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety. Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]